Integer Holdings Co. (NYSE:ITGR - Get Free Report) Director Martin C. Maxwell sold 8,720 shares of the firm's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $120.56, for a total value of $1,051,283.20. Following the completion of the transaction, the director now owns 22,170 shares in the company, valued at $2,672,815.20. The trade was a 28.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Integer Stock Performance
ITGR traded up $0.70 during midday trading on Monday, reaching $122.03. The company had a trading volume of 383,875 shares, compared to its average volume of 375,849. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average of $118.81 and a two-hundred day moving average of $128.02. The company has a market cap of $4.26 billion, a P/E ratio of 36.32, a P/E/G ratio of 1.72 and a beta of 0.98. Integer Holdings Co. has a 1 year low of $104.93 and a 1 year high of $146.36.
Integer (NYSE:ITGR - Get Free Report) last released its earnings results on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. Integer had a return on equity of 11.65% and a net margin of 6.92%. The firm had revenue of $437.39 million during the quarter, compared to analysts' expectations of $428.51 million. During the same quarter last year, the business posted $1.14 earnings per share. The firm's revenue was up 7.3% on a year-over-year basis. As a group, equities research analysts predict that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.
Analyst Ratings Changes
ITGR has been the subject of a number of recent analyst reports. Citigroup raised shares of Integer from a "hold" rating to a "strong-buy" rating and increased their target price for the company from $133.00 to $140.00 in a research report on Thursday, May 22nd. Raymond James lifted their target price on Integer from $145.00 to $150.00 and gave the stock an "outperform" rating in a research note on Friday, April 25th. Oppenheimer lowered Integer from an "outperform" rating to a "market perform" rating in a report on Friday, February 21st. Truist Financial set a $150.00 target price on Integer and gave the company a "buy" rating in a report on Friday, April 25th. Finally, KeyCorp reduced their target price on Integer from $154.00 to $145.00 and set an "overweight" rating for the company in a report on Monday, April 21st. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $145.00.
Read Our Latest Research Report on Integer
Institutional Investors Weigh In On Integer
Hedge funds have recently bought and sold shares of the business. Mather Group LLC. lifted its stake in shares of Integer by 304.3% in the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 143 shares during the last quarter. Lee Danner & Bass Inc. bought a new stake in shares of Integer in the 4th quarter valued at approximately $27,000. AdvisorNet Financial Inc bought a new stake in shares of Integer in the 1st quarter valued at approximately $28,000. Opal Wealth Advisors LLC bought a new stake in shares of Integer in the 1st quarter valued at approximately $28,000. Finally, Bessemer Group Inc. lifted its stake in shares of Integer by 73.1% in the 1st quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 99.29% of the company's stock.
About Integer
(
Get Free Report)
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Further Reading
Before you consider Integer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integer wasn't on the list.
While Integer currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
